Skip to search formSkip to main contentSkip to account menu

seclazone

Known as: 7-chloro-3,3a-dihydro-2H,9H-isoxazolo(3,2-b)(1,3)benzoxazin-9-one 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Benzoxazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1977
Highly Cited
1977
Effects of antiinflammatory agents on mouse skin tumor promotion, epidermal DNA synthesis, phorbol ester-induced cellular proliferation, and production of plasminogen activator.
The antinflammatory ateroids fluocinoine acetonide, fluocinonide, and fluclorolone acetonide were found to be very… 
1977
1977
The effects of anti-inflammatory agents on skin tumor initiation and aryl hydrocarbon hydroxylase.
The effects of various clinically used anti-inflammatory agents on mouse skin tumorigenesis and aryl hydrocarbon hydroxylase (AHH… 
1974
1974
The metabolic fate of seclazone in man.
1974
1974
Optimal conditions for the hydrolysis of seclazone by rat hepatic microsomes.
1973
1973
The pharmacological properties of seclazone (7-chloro-3,3a-dihydro-2H, 9H-isoxazolo (3,2-b) (1,3) benzoxazin-9-one) a new anti-inflammatory agent.
Seclazone possesses anti-inflammatory, analgesic and antipyretic properties. It effectively suppresses the development of… 
1973
1973
Absorption, distribution, and metabolic fate of seclazone (7-chloro-3,3a-dihydro-2H,9H-isoxazolo(3,2-b) (1,3)benzoxazin-9-one).
The absorption, distribution, and metabolic fate of seclazone was studied in the rat, dog, and rhesus monkey. Seclazone is… 
1973
1973
The in vivo antibradykinin activity of seclazone (7-chloro-3,3a-dihydro-2H,9H-isoxazolo(3,2-b) (1,3)benzoxazin-9-one), a new anti-inflammatory agent.
Seclazone, a new antipyretic and anti-inflammatory compound with diuretic properties significantly inhibits the bradykinin… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)